Catalent, Inc. (NYSE:CTLT) Q3 2022 Earnings Conference Call May 3, 2022 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Chiminski - Chair and Chief Executive Officer Alessandro Maselli - President and Chief Operating Officer Thomas Castellano - Senior Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Luke Sergott - Barclays Capital Jacob Johnson - Stephens, Inc. Julia Qin - J.P. Morgan Sean Dodge - RBC Capital Markets ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------------------|---------------------------- ...

Q3'22 Earnings Call Presentation May 3, 2022 Agenda John Chiminski, Chair & Chief Executive Officer • Q3'22 financial highlights • Corporate Responsibility Alessandro Maselli, President & Chief Operating Officer • Operational highlights Thomas Castellano, Senior VP & Chief Financial Officer • Q3'22 financial performance • Capitalization review • Guidance Question & Answer Session 2 Disclaimer Statement Forward-Looking Statements This release contains both historical and forward-looking statements. All state ...

Financial Data and Key Metrics Changes - Catalent's net revenue for Q2 was over $1.2 billion, increasing by 34% as reported or 35% in constant currency compared to Q2 of fiscal 2021 [9] - Adjusted EBITDA for Q2 was $310 million, up 39% on both an as-reported and constant currency basis compared to the same period last year [10] - Adjusted net income for Q2 was $163 million or $0.90 per diluted share, an increase from $0.63 per diluted share in the prior-year period [11] Business Segment Data and Key Metrics Changes - The Biologics segment generated net revenue of $638 million, a 60% increase compared to Q2 of fiscal 2021, driven by high demand for COVID-19 related programs [40] - The Softgel and Oral Technologies segment reported net revenue of $329 million, a 36% increase, with the acquisition of Bettera contributing significantly to this growth [45] - The Clinical Supply Services segment posted net revenue of $99 million, representing a 7% growth over the same period last year [51] Market Data and Key Metrics Changes - The Biologics segment now accounts for 52% of net revenue, up from 44% in Q2 of fiscal 2021 and 31% in Q2 of fiscal 2020 [39] - The backlog for the Clinical Supply Services segment was $529 million, up 18% from the previous year [52] Company Strategy and Development Direction - Catalent plans to continue expanding its global network and invest in growth-driving capabilities, particularly in biotherapeutics and cell and gene therapy [26] - The company has raised its long-term net revenue growth rate for the Softgel and Oral Technologies segment to 6% to 8% following the Bettera acquisition [14] - Catalent's long-term strategic plan anticipates continued growth even as COVID-19 related revenue declines in the coming years [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow the Biologics segment at a rate of 10% to 15% in the long term, despite expected deceleration in COVID-19 related revenue [66] - The company is addressing regulatory observations from the FDA with a focus on maintaining high standards of quality and compliance [36][68] Other Important Information - Catalent's net leverage ratio as of December 31, 2021, was 2.8 times, below the long-term target of 3.0 times [55] - The company expects full fiscal year net revenue in the range of $4.74 billion to $4.86 billion, representing growth of 19% to 22% [58] Q&A Session Summary Question: Contribution of COVID-19 programs to Biologics revenue - Management indicated that while they cannot provide specific figures, they expect COVID-19 revenue to be higher than the previous year's $550 million and to continue contributing into fiscal 2023 [63][64] Question: Timeline for remediation efforts at the Brussels facility - Management did not provide specific timelines but confirmed that significant resources are being deployed to address the issues [68] Question: Impact of remediation on new RFPs and win rates - Management stated that they have not experienced a slowdown in commercial activity and demand for services remains high [72] Question: Financial impact of remediation costs - Management noted that while there will be additional costs due to remediation, these have been factored into the updated guidance [74] Question: Capacity utilization across facilities - Management confirmed that many facilities are operating at high capacity, particularly in drug product assets, and additional capacity is expected to come online [94][95]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) _____________________________ Catalent, Inc. (Exact name of registrant as specifie ...

Q2'22 Earnings Call Presentation February 1, 2022 Agenda John Chiminski, Chair & Chief Executive Officer • Q2'22 highlights • CEO transition plan Alessandro Maselli, President & Chief Operating Officer • FY'26 financial targets Thomas Castellano, Senior VP & Chief Financial Officer • Q2'22 financial performance • Capitalization review • FY'22 financial guidance Question & Answer Session 2 Disclaimer Statement Forward-Looking Statements This release contains both historical and forward-looking statements. Al ...

Catalent. CATALENT, INC. INVESTOR PRESENTATION JANUARY 10, 2022 Catalent. Where science meets art. Forward-looking statements This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be iden ...

Catalent. Q1'22 Earnings Call Presentation November 2, 2021 DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied." Agenda | --- | |--------------------------------------------------------| | John Chiminski, Chair & Chief Executive Officer | | Q1'22 financial highlights | | Q1'22 operational highlights | | Thomas Castellano, Senior VP & Chief Financial Officer | | Q1'22 business segment financial performance | | EBITDA & Adjusted EBITDA | | Adjusted Net Income and Adjusted Net Inco ...

Catalent, Inc. (NYSE:CTLT) Q3 Earnings Conference Call November 2, 2021 8:15 AM ET Company Participants John Chiminski – Chair and Chief Executive Officer Paul Surdez – Vice President of Investor Relations Thomas Castellano – Senior Vice President and Chief Financial Officer Conference Call Participants Tycho Peterson – JP Morgan Jacob Johnson – Stephens David Windley – Jefferies Unidentified Analyst – Morgan Stanley John Kreger – William Blair Jack Meehan – Nephron Paul Knight – KeyBanc Capital Markets Tho ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) _____________________________ Catalent, Inc. (Exact name of registrant as specifi ...